1032350-13-2

Basic information

• Product Name: MK-2206 2HCl
• Synonyms: MK-2206;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride;MK-2206 Dihydrochloride;8-[4-(1-AMinocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one Hydrochloride;MK-2206 2HCl;8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride MK-2206;MK-2206 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride
• CAS NO: 1032350-13-2
• Molecular Formula: C25H21N5O
• Molecular Weight: 407.46714
• Product Categories: Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitor;PI3K/Akt/mTOR;Inhibitors;Akt;mTOR;PI3K
• Mol File: 1032350-13-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to 10 mg/ml with warming)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: MK-2206 2HCl(CAS DataBase Reference)
• NIST Chemistry Reference: MK-2206 2HCl(1032350-13-2)
• EPA Substance Registry System: MK-2206 2HCl(1032350-13-2)

Safety Data

• Hazardous Substances Data: 1032350-13-2(Hazardous Substances Data)

Usage

Description

MK-2206 2HCl is a potent and selective allosteric inhibitor of Akt, a protein kinase involved in various cellular processes, including cell proliferation, apoptosis, and tumorigenesis. It has demonstrated significant antitumor efficacy in both in vitro and in vivo studies, making it a promising candidate for cancer treatment.

Uses

Used in Anticancer Applications:
MK-2206 2HCl is used as an antitumor agent for its ability to inhibit the AKT responses, which play a crucial role in tumor growth and progression. The compound has shown a significant synergistic effect on tumor growth when combined with other targeted small-molecule drugs, such as AZD6244, which inhibits MEK responses. This combination has led to increased survival rates in mice bearing highly aggressive human lung tumors.
Used in Drug Delivery Systems:
MK-2206 2HCl is used as a potent AKT inhibitor for enhancing the efficacy of standard chemotherapeutic agents. By inhibiting AKT, it can decrease insulin-stimulated glucose uptake, glycogen synthesis, and glycogen synthase activity in rat muscle. Additionally, MK-2206 has induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis, further contributing to its potential as a therapeutic agent in cancer treatment.

References

1) Hirai?et al.?(2010),?MK-2206, an Allosteric Akt inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular targeted Drugs In vitro and In vivo; Mol. Cancer Ther.?9?1956 2) Lai?et al.?(2012),?A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle; Biochem. J.?447?137 3) Jiao?et al.?(2013),?MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death; Mol. Cell Biochem.?382?217

Upstream product

• 338452-92-9 4-amino-2-chloronicotinaldehyde 
• 893423-62-6 tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate 

Relevant articles and documents

IL-23 ANTAGONISTS FOR TREATMENT OR PREVENTION OF SKIN RASH ASSOCIATED WITH TREATMENT WITH P13K/AKT PATHWAY INHIBITORS

The present invention provides methods for use of interleukin-23 (IL-23) antagonists to treat or prevent skin rash associated with treatment with PI3K/AKT pathway inhibitors, such as treatment of cancer.